Fulcrum Therapeutics, Inc.
For the period ended Sep 30, 2025. Filed Oct 29, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Oct 29, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Other Information
Item 5. Other Information.
(a) None.
(b) None.
(c)Director and Officer Trading Plans and Arrangements
On August 1, 2025, Robert J. Gould, a member of ourboard of directors, adopted a trading plan for the potential sale of up to 180,000 shares of our common stock. The trading plan is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act and is expected to remain in effect until December 15, 2026.
On August 8, 2025, Curtis Oltmans, ourchief legal officer, adopted a trading plan for the potential sale of up to 12,186 shares of our common stock and for the potential exercise of vested stock options and the associated sale of up to 40,000 shares of our common stock. The trading plan is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act and is expected to remain in effect until June 30, 2026.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.